Vedolizumab therapy in common variable immune deficiency associated enteropathy: A case series.
Adult
Aged
Antibodies, Monoclonal, Humanized
/ therapeutic use
Common Variable Immunodeficiency
/ complications
Female
Gastrointestinal Agents
/ therapeutic use
Humans
Inflammation
Intestinal Diseases
/ drug therapy
Malabsorption Syndromes
/ etiology
Male
Malnutrition
/ etiology
Middle Aged
Parenteral Nutrition
Treatment Failure
CVID
Common variable immune deficiency
Enteropathy
Vedolizumab
Journal
Clinical immunology (Orlando, Fla.)
ISSN: 1521-7035
Titre abrégé: Clin Immunol
Pays: United States
ID NLM: 100883537
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
09
02
2020
accepted:
10
02
2020
pubmed:
15
2
2020
medline:
21
10
2020
entrez:
15
2
2020
Statut:
ppublish
Résumé
A number of gastrointestinal complications occur in common variable immunodeficiency (CVID). Infections are one cause, but various forms of severe non-infectious enteropathy also lead to substantial morbidity. The presence of T cell lymphocytic infiltrates in the mucosa have suggested that vedolizumab, a humanized monoclonal antibody which binds to alpha4 beta7 integrin and inhibits the migration of effector T-lymphocytes into gastrointestinal tissues, would be an effective treatment. A previous report of 3 CVID cases suggested benefit in 2 subjects. In this study 7 CVID patients with severe enteropathy were treated with vedolizumab. Four of the 7 completed vedolizumab induction therapy but 3 subjects had acute decompensation during induction and treatment was stopped. While one subject showed improvement, 6 of the 7 patients were withdrawn from therapy. While vedolizumab may be of use in some CVID subjects, it was not ultimately found helpful in most of these patients.
Identifiants
pubmed: 32058070
pii: S1521-6616(20)30083-8
doi: 10.1016/j.clim.2020.108362
pmc: PMC7310569
mid: NIHMS1599293
pii:
doi:
Substances chimiques
Antibodies, Monoclonal, Humanized
0
Gastrointestinal Agents
0
vedolizumab
9RV78Q2002
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
108362Subventions
Organisme : NIAID NIH HHS
ID : P01 AI061093
Pays : United States
Organisme : NIAID NIH HHS
ID : R18 AI048693
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI101093
Pays : United States
Organisme : NIAID NIH HHS
ID : U24 AI086037
Pays : United States
Informations de copyright
Copyright © 2020. Published by Elsevier Inc.
Références
Am J Surg Pathol. 2007 Dec;31(12):1800-12
pubmed: 18043034
J Allergy Clin Immunol. 2014 Jul;134(1):116-26
pubmed: 24582312
Am J Surg Pathol. 1996 Oct;20(10):1240-52
pubmed: 8827031
J Allergy Clin Immunol. 2017 Mar;139(3):1043-1046.e5
pubmed: 27908448
Clin Immunol. 2017 Jul;180:80-83
pubmed: 28323147
Scand J Gastroenterol. 2019 Feb;54(2):164-168
pubmed: 31006294
Blood. 2012 Feb 16;119(7):1650-7
pubmed: 22180439
N Engl J Med. 2013 Aug 22;369(8):711-21
pubmed: 23964933
J Allergy Clin Immunol Pract. 2019 Jul - Aug;7(6):1763-1770
pubmed: 30776527
Am J Gastroenterol. 2019 Apr;114(4):648-655
pubmed: 30747770
Endoscopy. 2013;45(4):320-3
pubmed: 23325698
Am J Gastroenterol. 2016 Oct;111(10):1467-1475
pubmed: 27527747
Curr Gastroenterol Rep. 2016 Apr;18(4):17
pubmed: 26951230
J Clin Immunol. 2020 Jan;40(1):24-64
pubmed: 31953710
Gastroenterology. 2006 Sep;131(3):748-56
pubmed: 16952544
Am J Gastroenterol. 2010 Oct;105(10):2262-75
pubmed: 20551941
Blood. 2008 Jul 15;112(2):277-86
pubmed: 18319398
Am J Gastroenterol. 2017 Oct;112(10):1621
pubmed: 28978958
Inflamm Bowel Dis. 2020 Mar 4;26(4):e22-e23
pubmed: 32002555
J Allergy Clin Immunol Pract. 2016 Jan-Feb;4(1):38-59
pubmed: 26563668
J Allergy Clin Immunol. 2016 Apr;137(4):1206-1215.e6
pubmed: 26542033